Fig. 8From: TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancerAssessment of response of high- and low-risk patients with BLCA to immunotherapy and potential drugs. A–D Immunotherapy response of BLCA patients in high- and low-risk groups. E–H The effect of immunotherapy between different subtypes. I–P The sensitivity of different drugs between the high- and low- risk groupsBack to article page